Which has preferable valuation & earnings, ZBH or PEN?

Zimmer Biomet has higher revenue and earnings than Penumbra. Zimmer Biomet is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zimmer Biomet $8.41B 2.14 $705.20M $3.85 24.14 Penumbra $1.40B 8.97 $177.69M $4.34 73.80

Is ZBH or PEN more profitable?

Penumbra has a net margin of 11.76% compared to Zimmer Biomet's net margin of 9.05%. Zimmer Biomet's return on equity of 13.24% beat Penumbra's return on equity. Company Net Margins Return on Equity Return on Assets Zimmer Biomet 9.05% 13.24% 7.28% Penumbra 11.76% 10.87% 8.45%

Does the media refer more to ZBH or PEN?

In the previous week, Penumbra had 6 more articles in the media than Zimmer Biomet. MarketBeat recorded 24 mentions for Penumbra and 18 mentions for Zimmer Biomet. Penumbra's average media sentiment score of 1.27 beat Zimmer Biomet's score of 1.24 indicating that Penumbra is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 14 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Penumbra 19 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, ZBH or MDLN?

Medline has higher revenue and earnings than Zimmer Biomet. Zimmer Biomet is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zimmer Biomet $8.41B 2.14 $705.20M $3.85 24.14 Medline $29.14B 1.81 $1.16B $0.32 125.62

Does the media favor ZBH or MDLN?

In the previous week, Zimmer Biomet had 4 more articles in the media than Medline. MarketBeat recorded 18 mentions for Zimmer Biomet and 14 mentions for Medline. Zimmer Biomet's average media sentiment score of 1.24 beat Medline's score of 1.19 indicating that Zimmer Biomet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 14 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medline 10 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to GEHC or ZBH?

In the previous week, GE HealthCare Technologies had 10 more articles in the media than Zimmer Biomet. MarketBeat recorded 28 mentions for GE HealthCare Technologies and 18 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 1.24 beat GE HealthCare Technologies' score of 0.67 indicating that Zimmer Biomet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GE HealthCare Technologies 10 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Zimmer Biomet 14 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ZBH or PHG?

Zimmer Biomet presently has a consensus price target of $100.70, suggesting a potential upside of 8.35%. Given Zimmer Biomet's stronger consensus rating and higher possible upside, analysts plainly believe Zimmer Biomet is more favorable than Koninklijke Philips. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zimmer Biomet 4 Sell rating(s) 12 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.21 Koninklijke Philips 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75

Does the media refer more to ZBH or PHG?

In the previous week, Zimmer Biomet had 15 more articles in the media than Koninklijke Philips. MarketBeat recorded 18 mentions for Zimmer Biomet and 3 mentions for Koninklijke Philips. Zimmer Biomet's average media sentiment score of 1.24 beat Koninklijke Philips' score of 0.00 indicating that Zimmer Biomet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zimmer Biomet 14 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Koninklijke Philips 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SOLV or ZBH?

In the previous week, Zimmer Biomet had 10 more articles in the media than Solventum. MarketBeat recorded 18 mentions for Zimmer Biomet and 8 mentions for Solventum. Zimmer Biomet's average media sentiment score of 1.24 beat Solventum's score of 1.15 indicating that Zimmer Biomet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solventum 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zimmer Biomet 14 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zimmer Biomet (ZBH) Competitors

$92.94 +1.59 (+1.74%)

As of 01:39 PM Eastern

Compare

ZBH vs. PEN, MDLN, GEHC, PHG, and SOLV

Should you buy Zimmer Biomet stock or one of its competitors? MarketBeat compares Zimmer Biomet with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zimmer Biomet include Penumbra (PEN), Medline (MDLN), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), and Solventum (SOLV). These companies are all part of the "medical equipment" industry.

How does Zimmer Biomet compare to Penumbra?

Zimmer Biomet (NYSE:ZBH) and Penumbra (NYSE:PEN) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Zimmer Biomet has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, Penumbra has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by insiders. Comparatively, 2.9% of Penumbra shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Zimmer Biomet currently has a consensus target price of $100.70, suggesting a potential upside of 8.35%. Penumbra has a consensus target price of $360.33, suggesting a potential upside of 12.50%. Given Penumbra's higher probable upside, analysts clearly believe Penumbra is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	4 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.21
Penumbra	1 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.11

Penumbra has a net margin of 11.76% compared to Zimmer Biomet's net margin of 9.05%. Zimmer Biomet's return on equity of 13.24% beat Penumbra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Penumbra	11.76%	10.87%	8.45%

Zimmer Biomet has higher revenue and earnings than Penumbra. Zimmer Biomet is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.41B	2.14	$705.20M	$3.85	24.14
Penumbra	$1.40B	8.97	$177.69M	$4.34	73.80

In the previous week, Penumbra had 6 more articles in the media than Zimmer Biomet. MarketBeat recorded 24 mentions for Penumbra and 18 mentions for Zimmer Biomet. Penumbra's average media sentiment score of 1.27 beat Zimmer Biomet's score of 1.24 indicating that Penumbra is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	14 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	19 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Penumbra beats Zimmer Biomet on 10 of the 17 factors compared between the two stocks.

How does Zimmer Biomet compare to Medline?

Zimmer Biomet (NYSE:ZBH) and Medline (NASDAQ:MDLN) are both large-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Medline has higher revenue and earnings than Zimmer Biomet. Zimmer Biomet is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.41B	2.14	$705.20M	$3.85	24.14
Medline	$29.14B	1.81	$1.16B	$0.32	125.62

Zimmer Biomet has a net margin of 9.05% compared to Medline's net margin of 0.00%. Zimmer Biomet's return on equity of 13.24% beat Medline's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Medline	N/A	N/A	N/A

88.9% of Zimmer Biomet shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by insiders. Comparatively, 0.8% of Medline shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Zimmer Biomet had 4 more articles in the media than Medline. MarketBeat recorded 18 mentions for Zimmer Biomet and 14 mentions for Medline. Zimmer Biomet's average media sentiment score of 1.24 beat Medline's score of 1.19 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	14 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Medline	10 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zimmer Biomet presently has a consensus price target of $100.70, indicating a potential upside of 8.35%. Medline has a consensus price target of $50.54, indicating a potential upside of 25.72%. Given Medline's stronger consensus rating and higher probable upside, analysts clearly believe Medline is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	4 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.21
Medline	1 Sell rating(s)	5 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.79

Summary

Zimmer Biomet beats Medline on 9 of the 15 factors compared between the two stocks.

How does Zimmer Biomet compare to GE HealthCare Technologies?

GE HealthCare Technologies (NASDAQ:GEHC) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

GE HealthCare Technologies pays an annual dividend of $0.14 per share and has a dividend yield of 0.2%. Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 1.0%. GE HealthCare Technologies pays out 3.3% of its earnings in the form of a dividend. Zimmer Biomet pays out 24.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GE HealthCare Technologies has raised its dividend for 1 consecutive years.

GE HealthCare Technologies has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

82.1% of GE HealthCare Technologies shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 0.4% of GE HealthCare Technologies shares are owned by insiders. Comparatively, 1.3% of Zimmer Biomet shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GE HealthCare Technologies has a net margin of 9.10% compared to Zimmer Biomet's net margin of 9.05%. GE HealthCare Technologies' return on equity of 20.46% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GE HealthCare Technologies	9.10%	20.46%	5.73%
Zimmer Biomet	9.05%	13.24%	7.28%

GE HealthCare Technologies presently has a consensus target price of $76.41, indicating a potential upside of 22.98%. Zimmer Biomet has a consensus target price of $100.70, indicating a potential upside of 8.35%. Given GE HealthCare Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe GE HealthCare Technologies is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GE HealthCare Technologies	1 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43
Zimmer Biomet	4 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.21

In the previous week, GE HealthCare Technologies had 10 more articles in the media than Zimmer Biomet. MarketBeat recorded 28 mentions for GE HealthCare Technologies and 18 mentions for Zimmer Biomet. Zimmer Biomet's average media sentiment score of 1.24 beat GE HealthCare Technologies' score of 0.67 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GE HealthCare Technologies	10 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Zimmer Biomet	14 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GE HealthCare Technologies has higher revenue and earnings than Zimmer Biomet. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GE HealthCare Technologies	$20.63B	1.37	$2.08B	$4.18	14.86
Zimmer Biomet	$8.41B	2.14	$705.20M	$3.85	24.14

Summary

GE HealthCare Technologies beats Zimmer Biomet on 12 of the 20 factors compared between the two stocks.

How does Zimmer Biomet compare to Koninklijke Philips?

Zimmer Biomet (NYSE:ZBH) and Koninklijke Philips (NYSE:PHG) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

In the previous week, Zimmer Biomet had 15 more articles in the media than Koninklijke Philips. MarketBeat recorded 18 mentions for Zimmer Biomet and 3 mentions for Koninklijke Philips. Zimmer Biomet's average media sentiment score of 1.24 beat Koninklijke Philips' score of 0.00 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	14 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Koninklijke Philips	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zimmer Biomet pays an annual dividend of $0.96 per share and has a dividend yield of 1.0%. Koninklijke Philips pays an annual dividend of $0.84 per share and has a dividend yield of 3.2%. Zimmer Biomet pays out 24.9% of its earnings in the form of a dividend. Koninklijke Philips pays out 71.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 13.7% of Koninklijke Philips shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Koninklijke Philips has higher revenue and earnings than Zimmer Biomet. Koninklijke Philips is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.41B	2.14	$705.20M	$3.85	24.14
Koninklijke Philips	$20.17B	1.28	$1.01B	$1.17	22.39

Zimmer Biomet has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market. Comparatively, Koninklijke Philips has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

Zimmer Biomet has a net margin of 9.05% compared to Koninklijke Philips' net margin of 5.49%. Koninklijke Philips' return on equity of 13.51% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Koninklijke Philips	5.49%	13.51%	5.48%

Zimmer Biomet presently has a consensus price target of $100.70, suggesting a potential upside of 8.35%. Given Zimmer Biomet's stronger consensus rating and higher possible upside, analysts plainly believe Zimmer Biomet is more favorable than Koninklijke Philips.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	4 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.21
Koninklijke Philips	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

Zimmer Biomet beats Koninklijke Philips on 14 of the 19 factors compared between the two stocks.

How does Zimmer Biomet compare to Solventum?

Solventum (NYSE:SOLV) and Zimmer Biomet (NYSE:ZBH) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Solventum currently has a consensus price target of $81.91, indicating a potential upside of 1.20%. Zimmer Biomet has a consensus price target of $100.70, indicating a potential upside of 8.35%. Given Zimmer Biomet's higher possible upside, analysts plainly believe Zimmer Biomet is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
Zimmer Biomet	4 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.21

Solventum has higher earnings, but lower revenue than Zimmer Biomet. Solventum is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.68	$1.56B	$8.16	9.92
Zimmer Biomet	$8.41B	2.14	$705.20M	$3.85	24.14

88.9% of Zimmer Biomet shares are held by institutional investors. 0.2% of Solventum shares are held by company insiders. Comparatively, 1.3% of Zimmer Biomet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Solventum has a net margin of 17.33% compared to Zimmer Biomet's net margin of 9.05%. Solventum's return on equity of 23.51% beat Zimmer Biomet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Zimmer Biomet	9.05%	13.24%	7.28%

In the previous week, Zimmer Biomet had 10 more articles in the media than Solventum. MarketBeat recorded 18 mentions for Zimmer Biomet and 8 mentions for Solventum. Zimmer Biomet's average media sentiment score of 1.24 beat Solventum's score of 1.15 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solventum	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	14 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Solventum has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, Zimmer Biomet has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

Summary

Zimmer Biomet beats Solventum on 10 of the 17 factors compared between the two stocks.

Get Zimmer Biomet News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZBH vs. The Competition

Export

Metric	Zimmer Biomet	MED PRODUCTS Industry	Medical Sector	NYSE Exchange
Market Cap	$17.98B	$8.91B	$6.95B	$23.57B
Dividend Yield	1.07%	2.54%	2.67%	4.20%
P/E Ratio	24.14	18.64	27.14	31.06
Price / Sales	2.14	6.80	523.10	19.49
Price / Cash	6.65	18.46	26.39	18.54
Price / Book	1.45	3.22	10.48	4.77
Net Income	$705.20M	$230.22M	$3.60B	$1.07B
7 Day Performance	3.62%	-1.03%	-1.03%	0.49%
1 Month Performance	0.02%	-3.38%	-2.37%	0.12%
1 Year Performance	-4.77%	-6.56%	18.86%	14.37%

Zimmer Biomet Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZBH Zimmer Biomet	3.4914 of 5 stars	$92.94 +1.7%	$100.70 +8.4%	-6.4%	$17.98B	$8.41B	24.14	17,000	Positive News Analyst Upgrade
PEN Penumbra	2.769 of 5 stars	$318.18 0.0%	$360.33 +13.2%	+36.6%	$12.52B	$1.40B	73.31	4,700	News Coverage Positive News
MDLN Medline	4.5509 of 5 stars	$38.88 -2.3%	$50.54 +30.0%	N/A	$52.27B	$28.43B	121.50	45,000	Positive News
GEHC GE HealthCare Technologies	4.8406 of 5 stars	$62.83 -0.4%	$76.41 +21.6%	-21.9%	$28.69B	$20.63B	15.03	54,000	Positive News Upcoming Earnings Ex-Dividend
PHG Koninklijke Philips	1.9194 of 5 stars	$26.77 -0.7%	N/A	+0.0%	$26.49B	$20.17B	22.94	65,340	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ZBH) was last updated on 7/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zimmer Biomet (ZBH) Competitors

ZBH vs. PEN, MDLN, GEHC, PHG, and SOLV

How does Zimmer Biomet compare to Penumbra?

Summary

How does Zimmer Biomet compare to Medline?

Summary

How does Zimmer Biomet compare to GE HealthCare Technologies?

Summary

How does Zimmer Biomet compare to Koninklijke Philips?

Summary

How does Zimmer Biomet compare to Solventum?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBH vs. The Competition

Zimmer Biomet Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zimmer Biomet (ZBH) Competitors

ZBH vs. PEN, MDLN, GEHC, PHG, and SOLV

How does Zimmer Biomet compare to Penumbra?

Which has more volatility and risk, ZBH or PEN?

Do institutionals & insiders hold more shares of ZBH or PEN?

Do analysts recommend ZBH or PEN?

Is ZBH or PEN more profitable?

Which has preferable valuation & earnings, ZBH or PEN?

Does the media refer more to ZBH or PEN?

Summary

How does Zimmer Biomet compare to Medline?

Which has better valuation & earnings, ZBH or MDLN?

Is ZBH or MDLN more profitable?

Do insiders and institutionals believe in ZBH or MDLN?

Does the media favor ZBH or MDLN?

Do analysts recommend ZBH or MDLN?

Summary

How does Zimmer Biomet compare to GE HealthCare Technologies?

Is GEHC or ZBH a better dividend stock?

Which has more volatility and risk, GEHC or ZBH?

Do insiders & institutionals have more ownership in GEHC or ZBH?

Is GEHC or ZBH more profitable?

Do analysts rate GEHC or ZBH?

Does the media refer more to GEHC or ZBH?

Which has preferable valuation and earnings, GEHC or ZBH?

Summary

How does Zimmer Biomet compare to Koninklijke Philips?

Does the media refer more to ZBH or PHG?

Is ZBH or PHG a better dividend stock?

Do institutionals & insiders have more ownership in ZBH or PHG?

Which has preferable earnings & valuation, ZBH or PHG?

Which has more volatility & risk, ZBH or PHG?

Is ZBH or PHG more profitable?

Do analysts rate ZBH or PHG?

Summary

How does Zimmer Biomet compare to Solventum?

Do analysts recommend SOLV or ZBH?

Which has higher valuation & earnings, SOLV or ZBH?

Do insiders and institutionals believe in SOLV or ZBH?

Is SOLV or ZBH more profitable?

Does the media prefer SOLV or ZBH?

Which has more risk and volatility, SOLV or ZBH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZBH vs. The Competition

Zimmer Biomet Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools